Literature DB >> 4391844

In vitro activity of coumermycin A1.

J Fedorko, S Katz, H Allnoch.   

Abstract

The in vitro activity of coumermycin A(1) was compared with that of novobiocin, ampicillin, and minocycline. Coumermycin was found to be the most active antibiotic of the four against Staphylococcus aureus. It was about 50 times more active than novobiocin or minocycline against the strains tested. Coumermycin also showed good activity against group A streptococci and pneumococci, moderate activity against Escherichia coli, indole-positive Proteus species, and Pseudomonas aeruginosa, and poor activity against Klebsiella-Enterobacter and enterococci. Against P. mirabilis, however, coumermycin activity was almost equal to that of ampicillin. The new antibiotic was further found to be greatly reduced in activity in the presence of plasma, but its minimal inhibitory concentration was not greatly affected by inoculum size. Coumermycin was found to be bacteriostatic in its action, and resistance to it developed slowly. Also, cross-resistance was present with novobiocin but absent with ampicillin or minocycline.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4391844      PMCID: PMC378103          DOI: 10.1128/am.18.5.869-873.1969

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  8 in total

1.  STUDIES ON COUMERMYCIN, A NEW ANTIBIOTIC. I. PRODUCTION, ISOLATION AND CHARACTERIZATION OF COUMERMYCIN A1.

Authors:  H KAWAGUCHI; H TSUKIURA; M OKANISHI; T MIYAKI; T OHMORI; K FUJISAWA; H KOSHIYAMA
Journal:  J Antibiot (Tokyo)       Date:  1965-01       Impact factor: 2.649

2.  STUDIES ON COUMERMYCIN. A NEW ANTIBIOTIC. II. STRUCTURE OF COUMERMYCIN A1.

Authors:  H KAWAGUCHI; T NAITO; H TSUKIURA
Journal:  J Antibiot (Tokyo)       Date:  1965-01       Impact factor: 2.649

3.  In vitro activity of minocycline, a new tetracycline.

Authors:  J Fedorko; S Katz; H Allnoch
Journal:  Am J Med Sci       Date:  1968-04       Impact factor: 2.378

4.  Further observations on chemotherapeutic activity of coumermycin A1. I. Activity against Neisseria meningitidis type A and meningopneumonitis.

Authors:  E Grunberg; R Cleeland; E Titsworth
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

5.  Semisynthetic coumermycins. I. Preparation of 3-acylamido-4-hydroxy-8-methyl-7-[3-O-(5-methyl-2-pyrrolylcarbonyl)noviosyloxy]coumarins.

Authors:  J G Keil; I R Hooper; M J Cron; O B Farbig; D E Nettleton
Journal:  J Antibiot (Tokyo)       Date:  1968-09       Impact factor: 2.649

6.  Susceptibility of staphylococci to new antimicrobial agents.

Authors:  P D Hoeprich
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

7.  Chemotherapeutic properties of coumermycin A1.

Authors:  E Grunberg; M Bennett
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

8.  Production, isolation, and synthesis of the coumermycins (sugordomycins), a new streptomycete antibiotic complex.

Authors:  J Berger; A J Schocher; A D Batcho; B Pecherer; O Keller; J Maricq; A E Karr; B P Vaterlaus; A Furlenmeier; H Speigelberg
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965
  8 in total
  3 in total

1.  Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.

Authors:  C M Perronne; R Malinverni; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  Effect of mg and ethylenediaminetetraacetate on the in vitro activity of coumermycin a(1) and novobiocin against gram-negative bacteria.

Authors:  R Cleeland; G Beskid; E Grunberg
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.